论文部分内容阅读
[目的]研究雌激素受体2(ERβ)与肝细胞肝癌(HCC)术后复发的相关性以及其潜在分子机制。[方法]通过q RT-PCR技术与Western Blot检测ERβ在HCC术后两年内复发的8例患者以及10例未复发患者癌组织样本内的表达差异。同时,利用三种交叉验证实验(留一交叉验证、十折交叉验证和蒙特卡罗交叉验证)分析ERβ表达对HCC样本的术后复发预后的分型准确性。此外,进一步预测ERβ下游调控基因,分析下游调控基因显著参与的生物学功能以及信号通路,探究其可能的分子机制。[结果]ERβ基因在术后复发的HCC样本中显著高表达,与术后复发明显相关,且通过交叉验证实验结果发现ERβ对HCC样本有较好的分型准确性,三种验证方法的分型准确率分别为75%(73%~76%)、73%(72%~73%)与71%(71%~72%)。最后通过对ERβ下游调控基因的功能富集分析发现,ERβ显著参与到细胞增殖、RNA转录等HCC术后发展相关的功能与通路中。[结论]ERβ具有良好的HCC术后复发预测效能,具有成为HCC术后复发分子标志物的潜力,具有一定的研究价值。
[Objective] To investigate the correlation between estrogen receptor 2 (ERβ) and postoperative recurrence of hepatocellular carcinoma (HCC) and its potential molecular mechanism. [Methods] The expression differences of ERβ in 8 cases of recurrent ERCC within 2 years and 10 cases of non-recurrent cancer tissues were detected by q RT-PCR and Western Blot. At the same time, we used three kinds of cross-validation experiments (leaving one cross-validation, ten-cross validation and Monte Carlo cross-validation) to analyze the accuracy of ERβ expression in the prognosis of postoperative recurrence of HCC. In addition, we further predicted the downstream regulatory genes of ERβ, analyzed the biological functions and signaling pathways involved in the downstream regulatory genes, and explored the possible molecular mechanisms. [Results] The ERβ gene was highly expressed in the postoperative recurrence of HCC samples, which was significantly correlated with postoperative recurrence. The results of cross validation showed that ERβ had a good typing accuracy for HCC samples. The scores of the three validation methods The accuracy rates were 75% (73% ~ 76%), 73% (72% ~ 73%) and 71% (71% ~ 72%) respectively. Finally, by functional enrichment analysis of ERβ downstream regulatory genes, we found that ERβ is significantly involved in the development of HCC related functions and pathways such as cell proliferation and RNA transcription. [Conclusion] ERβ has good predictive value of recurrence after HCC, and has the potential of becoming a molecular marker of recurrence after HCC.